The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron‐carbohydrate administration
Open Access
- 9 January 2023
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 98 (3) , 533-540
Abstract
Many disorders of iron homeostasis (e.g., iron overload) are associated with the dynamic kinetic profiles of multiple non‐transferrin bound iron (NTBI) species, chronic exposure to which is associated with deleterious end‐organ effects. Here we discuss the chemical nature of NTBI species, challenges with measuring NTBI in plasma, and the clinical relevance of NTBI exposure based on source (iron overload disorder vs. intravenous iron‐carbohydrate complex administration). NTBI is not a single entity but consists of multiple, often poorly characterized species, some of which are kinetically non‐exchangeable while others are relatively exchangeable. Prolonged presence of plasma NTBI is associated with excessive tissue iron accumulation in susceptible tissues, with consequences, such as endocrinopathy and heart failure. In contrast, intravenous iron‐carbohydrate nanomedicines administration leads only to transient NTBI appearance and lacks evidence for association with adverse clinical outcomes. Assays to measure plasma NTBI are typically technically complex and remain chiefly a research tool. There have been two general approaches to estimating NTBI: capture assays and redox‐activity assays. Early assays could not avoid capturing some iron from transferrin, thus overestimating NTBI. By contrast, some later assays may have promoted the donation of NTBI species to transferrin during the assay procedure, potentially underestimating NTBI levels. The levels of transferrin saturation at which NTBI species have been detectable have varied between different methodologies and between patient populations studied.Keywords
This publication has 76 references indexed in Scilit:
- Intravenous Iron Supplementation Practices and Short-Term Risk of Cardiovascular Events in Hemodialysis PatientsPLOS ONE, 2013
- Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation responseHaematologica, 2011
- Elevated Transferrin Saturation and Risk of DiabetesDiabetes Care, 2011
- The Pharmacokinetics and Pharmacodynamics of Iron PreparationsPharmaceutics, 2011
- Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiproneTranslational Research, 2010
- Iron-induced oxidative stress in haemodialysis patients: a pilot study on the impact of diabetesBioMetals, 2007
- Recent Insights into Interactions of Deferoxamine with Cellular and Plasma Iron Pools: Implications for Clinical UseAnnals of the New York Academy of Sciences, 2005
- The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremiaKidney International, 2002
- Transition Metals Bind to Glycated Proteins Forming Redox Active “Glycochelates”: Implications for the Pathogenesis of Certain Diabetic ComplicationsBiochemical and Biophysical Research Communications, 1998
- Acute iron poisoning: Assessment of severity and prognosisThe Journal of Pediatrics, 1970